


1. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
2. (2-(4-((r)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic Acid
3. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
4. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
5. Cetirizine (r)-form Dihydrochloride
6. Levocetirizine
7. Levocetirizine Hydrochloride
8. Levocetrizine
9. Ucb-28556
10. Xusal
11. Xyzal
1. 130018-87-0
2. Xyzal
3. Xusal
4. (r)-cetirizine Dihydrochloride
5. Levocetirizine Hcl
6. Levocetirizine Dihydrochloride [usan]
7. Cetirizine (r)-form Dihydrochloride
8. Ucb-28556
9. Sod6a38aga
10. Ucb 28556
11. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
12. (r)-2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
13. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
14. Nsc-758898
15. Levocetirizine Hydrochloride (jan)
16. (-)-cetirizine Dihydrochloride
17. 2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid;dihydrochloride
18. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic Acid Dihydrochloride
19. Levocetirizine (dihydrochloride)
20. Levocetirizine Hydrochloride [jan]
21. Levocetirizine 2hcl
22. Unii-sod6a38aga
23. Levocetirizine Dihcl
24. Mfcd07366507
25. Xyzal Allergy 24hr
26. Xyzal (tn)
27. Levocetirizinedihydrochloride
28. Schembl144375
29. Chembl1201190
30. Levocetirizine Hydrochloride,(s)
31. Dtxsid30926567
32. Bcp21544
33. Ac-549
34. Levocetirizine Dihydrochloride (usp)
35. S4849
36. Akos015994681
37. Ccg-269359
38. Cs-w011557
39. Hy-w010841
40. Ks-1177
41. Nsc 758898
42. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid 2hcl
43. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
44. Levocetirizine Hydrochloride [mart.]
45. L0264
46. Levocetirizine Dihydrochloride [vandf]
47. Levocetirizine(r)-cetirizine (hydrochloride)
48. D08118
49. Levocetirizine Dihydrochloride [usp-rs]
50. Levocetirizine Dihydrochloride [who-dd]
51. Levocetirizine Dihydrochloride, >=98% (hplc)
52. Cetirizine (r)-form Dihydrochloride [mi]
53. 018l870
54. Levocetirizine Dihydrochloride [orange Book]
55. Levocetirizine Dihydrochloride [usp Monograph]
56. Q27289313
57. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid Dihydrochloride
| Molecular Weight | 461.8 g/mol |
|---|---|
| Molecular Formula | C21H27Cl3N2O3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Exact Mass | 460.108726 g/mol |
| Monoisotopic Mass | 460.108726 g/mol |
| Topological Polar Surface Area | 53 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 443 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 4 | |
|---|---|
| Drug Name | Levocetirizine dihydrochloride |
| Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
| Active Ingredient | Levocetirizine dihydrochloride |
| Dosage Form | Tablet; Solution |
| Route | Oral |
| Strength | 2.5mg/5ml; 5mg |
| Market Status | Prescription |
| Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
| 2 of 4 | |
|---|---|
| Drug Name | Xyzal |
| PubMed Health | Levocetirizine (By mouth) |
| Drug Classes | Respiratory Agent |
| Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
| Active Ingredient | Levocetirizine dihydrochloride |
| Dosage Form | Tablet; Solution |
| Route | Oral |
| Strength | 2.5mg/5ml; 5mg |
| Market Status | Prescription |
| Company | Ucb |
| 3 of 4 | |
|---|---|
| Drug Name | Levocetirizine dihydrochloride |
| Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
| Active Ingredient | Levocetirizine dihydrochloride |
| Dosage Form | Tablet; Solution |
| Route | Oral |
| Strength | 2.5mg/5ml; 5mg |
| Market Status | Prescription |
| Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
| 4 of 4 | |
|---|---|
| Drug Name | Xyzal |
| PubMed Health | Levocetirizine (By mouth) |
| Drug Classes | Respiratory Agent |
| Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
| Active Ingredient | Levocetirizine dihydrochloride |
| Dosage Form | Tablet; Solution |
| Route | Oral |
| Strength | 2.5mg/5ml; 5mg |
| Market Status | Prescription |
| Company | Ucb |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)